Company intelligence / Profile preview

Guangdong Hybribio Biotech

Chaozhou, Guangdong, China

Ownership: Private
Employees: ~2205
Development stage: Other

Overview

Extensive clinical validation of HPV diagnostics (CFDA, CE-IVD, WHO EQA certified); COVID-19 RT-PCR kit CE-certified and widely deployed; small molecule topical gel (chloroquine phosphate) under clinical testing for condylomata acuminata.

Therapeutic areas: HematologyWomen's HealthInfectious DiseasesRare Diseases
Modalities: Diagnostic reagentSmall molecule drug
Industry: Molecular Diagnostics

Partnerships

MGI (sequencing/genomics platforms for precision medicine)University of Hong Kong (technology license for Flow-through Hybridization)

Beyond the preview

Go deeper on Guangdong Hybribio Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangdong Hybribio Biotech.

Explore the full profile